Copertina

Blood‐based biomarker prescreening with different testing combinations and cutoffs: A simulation study examining efficacy and cost‐effectiveness in Alzheimer's disease prevention studies

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Kenichiro Sato, Yoshiki Niimi, Ryoko Ihara, Atsushi Iwata, Kazushi Suzuki, Takeshi Iwatsubo
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	Alzheimer's & Dementia: Translational Research & Clinical Interventions
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Immediate reactions to amyloid PET disclosure in Japanese older adults without dementia
di: Kenichiro Sato, et al.
Pubblicazione: (2025)

Social media responses to the approval of lecanemab in Japan: sentiment analysis
di: Kenichiro Sato, et al.
Pubblicazione: (2024)

Blood biomarkers for Alzheimer's disease are correlated with measures of agitation and cognition in a randomized trial assessing the effects of escitalopram on agitation
di: Maansi Barnwal, et al.
Pubblicazione: (2026)

Developing educational materials to aid in Alzheimer's blood biomarker disclosure
di: Raymond R. Romano, et al.
Pubblicazione: (2025)

Assessing safety and efficacy in subpopulations in Alzheimer's disease clinical trials: contextualizing representativeness
di: Guogen Shan, et al.
Pubblicazione: (2025)

Simulation of Alzheimer's diagnostic flows with blood biomarker test options in Japan
di: Ataru Igarashi, et al.
Pubblicazione: (2025)

Cerebrospinal fluid biomarker profiling of diverse pathophysiological domains in Alzheimer's disease
di: Bianca A. Trombetta, et al.
Pubblicazione: (2024)

The impact of estimated cardiorespiratory fitness on Alzheimer's disease biomarkers and their relationships with cognitive decline
di: Adam J Paulsen, et al.
Pubblicazione: (2025)

Quantifying the societal impact of disease‐modifying therapies in Alzheimer's disease: a cost savings‐based approach
di: Kenichiro Sato, et al.
Pubblicazione: (2025)

Understanding the impact of amyloid beta targeted therapies on biomarkers and clinical endpoints in Alzheimer's disease
di: Ronald C. Petersen, et al.
Pubblicazione: (2025)

Study of the utility and impact of a plasma p‐tau181 Alzheimer's biomarker (SUITABLE)
di: Kyra O'Brien, et al.
Pubblicazione: (2026)

Estimating the optimal cutoff for the IGT‐AD Distress subscale adapted for amyloid PET results disclosure
di: Dianxu Ren, et al.
Pubblicazione: (2025)

Relationship between physical activity and biomarkers of pathology and neuroinflammation in preclinical autosomal‐dominant Alzheimer's disease
di: Edmarie Guzmán‐Vélez, et al.
Pubblicazione: (2024)

Real‐world relationship between blood biomarker‐based PhenoAge, metformin, and Alzheimer's disease
di: Yi Shi, et al.
Pubblicazione: (2026)

Leveraging recent advances in plasma biomarkers to optimize early proof of concept trials in Alzheimer's disease
di: Garrett B. Duncan, et al.
Pubblicazione: (2025)

Communicating Alzheimer's biomarker results to cognitively unimpaired research participants: Satisfaction, utility, and impact on research attitudes
di: Claire M. Erickson, et al.
Pubblicazione: (2024)

Personal value of Alzheimer's disease biomarker testing and result disclosure from the patient and care partner perspective
di: Khushbu J. Patel, et al.
Pubblicazione: (2024)

Understanding recent advances in non‐amyloid/non‐tau (NANT) biomarkers and therapeutic targets in Alzheimer's disease
di: Linda J. Van Eldik, et al.
Pubblicazione: (2024)

Pharmacokinetic/pharmacodynamic analyses of plasma pathophysiology biomarkers in subjects with early Alzheimer's disease following lecanemab treatment
di: Pratik Bhagunde, et al.
Pubblicazione: (2026)

Cognitive training, alone and combined with acetylcholinesterase inhibitors, in neurocognitive disorders: long‐term efficacy and the role of cognitive reserve on 30 months of intervention
di: Adele Ravelli, et al.
Pubblicazione: (2026)

APOE ‐associated disease risk and sex‐specific effects in Egyptian Alzheimer's disease: an exploratory study
di: Mai Othman, et al.
Pubblicazione: (2026)

Physical activity attenuates the association between allostatic load and early Alzheimer's disease‐related biomarkers in older adults
di: Géraldine Poisnel, et al.
Pubblicazione: (2026)

Sex differences in Alzheimer's disease blood biomarkers in a Caribbean population of African ancestry: The Tobago Health Study
di: Caterina Rosano, et al.
Pubblicazione: (2024)

Worth their weight in gray matter? A narrative review of cost‐effectiveness analyses of monoclonal antibodies for Alzheimer's disease
di: Tuyet Thao Nguyen, et al.
Pubblicazione: (2026)

Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients
di: Dawn C. Matthews, et al.
Pubblicazione: (2024)

What is older adults’ understanding of Alzheimer's disease research registries? Findings from 20 focus group studies
di: Litty Samuel, et al.
Pubblicazione: (2025)

Broad repetitive transcranial magnetic stimulation (rTMS) of the precuneus in Alzheimer's disease: A rationale and study design
di: Michael K. Leuchter, et al.
Pubblicazione: (2025)

Blood DNA methylation signature of cognitive reserve moderates the association between CSF tau pathology and memory in prodromal Alzheimer's disease
di: David Lukacsovich, et al.
Pubblicazione: (2026)

Cognitive and Alzheimer's disease biomarker effects of oral nicotinamide riboside (NR) supplementation in older adults with subjective cognitive decline and mild cognitive impairment
di: Chao‐Yi Wu, et al.
Pubblicazione: (2025)

Plasma amyloid beta biomarkers predict amyloid positivity and longitudinal clinical progression in mild cognitive impairment
di: Takuya Ataka, et al.
Pubblicazione: (2024)

Genetically proxied IL‐6 signaling and risk of Alzheimer's disease and lobar intracerebral hemorrhage: A drug target Mendelian randomization study
di: Evangelos Pavlos Myserlis, et al.
Pubblicazione: (2024)

Tau biology, biomarkers, and therapeutics
di: Bess Frost, et al.
Pubblicazione: (2025)

Identification of cerebrospinal fluid pharmacodynamic biomarkers and molecular correlates of brain activity in a Phase 2 clinical trial of the Alzheimer's disease drug candidate CT1812
di: Valentina Di Caro, et al.
Pubblicazione: (2025)

Generating real‐world evidence in early Alzheimer's disease: Considerations for applying the target trial emulation framework to study the safety of anti‐amyloid therapies
di: Xiaojuan Li, et al.
Pubblicazione: (2025)

Recruitment of mid‐life adults to a randomized clinical trial: The multicultural healthy diet study to reduce cognitive decline and Alzheimer's disease risk
di: Mindy J. Katz, et al.
Pubblicazione: (2025)

Pooling Alzheimer's disease clinical trial data to develop personalized medicine approaches is easier said than done: A proof‐of‐principle study and call to action
di: Mark A. Dubbelman, et al.
Pubblicazione: (2024)

APOLLOE4 Phase 3 study of oral ALZ‐801/valiltramiprosate in APOE ε4/ε4 homozygotes with early Alzheimer's disease: Trial design and baseline characteristics
di: Susan Abushakra, et al.
Pubblicazione: (2024)

The HOPE4MCI study: AGB101 treatment slows progression of entorhinal cortex atrophy in APOE ε4 non‐carriers with mild cognitive impairment due to Alzheimer's disease
di: Arnold Bakker, et al.
Pubblicazione: (2024)

Digital biomarkers: Redefining clinical outcomes and the concept of meaningful change
di: Maria Florencia Iulita, et al.
Pubblicazione: (2025)

Clinically meaningful outcomes in Alzheimer's disease and Alzheimer's disease related dementias trials
di: Luke E. Stoeckel, et al.
Pubblicazione: (2025)